Your skin will gradually return to its baseline tone once you stop treatments, typically over 3-6 months
Shortness of breath (dyspnoea) is not listed amongst the adverse effects in the Summary of Product Characteristics (SmPC) or patient information leaflet, and a causal association has not been established
Scientific References Jastreboff AM, Aronne LJ, Ahmad NN, et al
A: Research-grade AOD-9604 should be at least 98% pure, confirmed by HPLC (High-Performance Liquid Chromatography) analysis
The rates are remarkably similar across all three, despite their different mechanisms: Semaglutide: Nausea approximately 18%, diarrhea approximately 12%, vomiting approximately 8% Tirzepatide: Nausea 17-22% (dose dependent), diarrhea 13-16%, vomiting 6-10% Retatrutide: Nausea 16-25% (dose dependent), diarrhea 15-22%, vomiting 8-13% The pattern holds consistently
Compared to SGLT2 inhibitors (such as dapagliflozin or empagliflozin), another modern diabetes drug class, Rybelsus offers comparable glycaemic control and weight loss benefits